T2 Biosystems raises $15 million Series C round
May 25, 2010 by MassDevice staff
T2 Biosystems Inc. raises $15 million in a Series C funding round to bring its benchtop MRI-based diagnostic device to market.
T2 Biosystems Inc. raised about $15 million in a Series C funding round it plans to use to bring its benchtop MRI-based diagnostic device to market.
The Cambridge, Mass.-based firm said Physic Ventures led the round, along with new backers Arcus Ventures, RA Capital, Camros Capital, WS Investments and existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
Navigation
NEWS
MassDevice.com +3 | The top 3 med-tech stories for May 22, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
FDA's Ortho Panel supports down-classification of pedicle screw spinal systems
The FDA's Orthopedic & Rehabilitations Devices Panel agrees with the FDA's recommendations that...
EuroPCR: 1-year results continue to support Edwards' next-gen Sapien XT valve
Medical device company Edwards Lifesciences unveils 1-year results for its next-generation Sapien XT...
DePuy Pinnacle lawsuits: Judge orders J&J's DePuy Orthopaedics to produce compliance reports
A federal judge overseeing a raft of cases filed against Johnson & Johnson's DePuy Orthopaedics...
EuroPCR: Boston Scientific's Lotus TAVI bests rivals with less leakage
Medical device giant Boston Scientific touts very low rates of paravalvular leakage in 30-day results...
